Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer

NCT00537771 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00537771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00537771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2007
Completion date
December 31, 2011
Enrollment
384 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer